Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 5, 2010, Pages 898-902

  Jüngel, Astrid ^a   Ospelt, Caroline ^a   Lesch, Mark ^b   Thiel, Melissa ^b   Sunyer, Teresa ^b   Schorr, Olivier ^a   Michel, Beat A ^a   Gay, Renate E ^a   Kolling, Christoph ^c   Flory, Craig ^b   Gay, Steffen ^a   Neidhart, Michel ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b PFIZER INC   (United States)

^c SCHULTHESS CLINIC   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COLLAGEN; MATRIX METALLOPROTEINASE 13 INHIBITOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL MODEL; HUMAN; HUMAN TISSUE; IMPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RHEUMATOID ARTHRITIS; SCID MOUSE;

ADMINISTRATION, ORAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MICE; MICE, SCID; RABBITS; SYNOVIAL MEMBRANE;

EID: 77951586059     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.106021     Document Type: Article

References (35)

1. Müller-Ladner U, Ospelt C, Gay S, et al. Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res Ther 2007;9:223. (Pubitemid 351865980)
2. Yasuda T. Cartilage destruction by matrix degradation products. Mod Rheumatol 2006;16:197-205. (Pubitemid 44227338)
3. Clark IM, Parker AE. Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets 2003;7:19-34. (Pubitemid 36204586)
4. Rengel Y, Ospelt C, Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther 2007;9:221. (Pubitemid 351611900)
5. Knäuper V, López-Otin C, Smith B, et al. Biochemical characterization of human collagenase-3. J Biol Chem 1996;271:1544-1550
6. Monfort J, Tardif G, Reboul P, et al. Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site. Arthritis Res Ther 2006;8:R26.
7. Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007;282:27781-27791
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
9. Müller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607-1615 (Pubitemid 26363967)
10. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986;883:173-177
11. Fingleton B. MMPs as therapeutic targets - still a viable option? Semin Cell Dev Biol 2008;19:61-68 (Pubitemid 350235985)
12. Hegen M, Keith JC Jr, Collins M, et al. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 2008;67:1505-1515
13. Pierer M, Müller-Ladner U, Pap T, et al. The SCID mouse model: novel therapeutic targets - lessons from gene transfer. Springer Semin Immunopathol 2003;25:65-78. (Pubitemid 37000039)
14. Rutkauskaite E, Zacharias W, Schedel J, et al. Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2004;50:1448-1456 (Pubitemid 38608066)
15. Mitchell PG, Magna HA, Reeves LM, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996;97:761-768
16. Fraser A, Fearon U, Billinghurst RC, et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003;48:3085-3095 (Pubitemid 37409319)
17. Vincenti MP, Coon CI, Mengshol JA, et al. Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1). Biochem J 1998;331(Pt 1):341-346
18. Balbín M, Fueyo A, Knäuper V, et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 2001;276:10253-10262 (Pubitemid 37391937)
19. Ishikawa T, Nishigaki F, Miyata S, et al. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840. Eur J Pharmacol 2005;508:239-247 (Pubitemid 40169925)
20. Tardif G, Reboul P, Pelletier JP, et al. Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Mod Rheumatol 2004;14:197-204. (Pubitemid 39206663)
21. Dahlberg L, Billinghurst RC, Manner P, et al. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum 2000;43:673-682 (Pubitemid 30394960)
22. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007;13:333-346 (Pubitemid 46085282)
23. Beekman B, Drijfhout JW, Ronday HK, et al. Fluorogenic MMP activity assay for plasma including MMPs complexed to alpha 2-macroglobulin. Ann N Y Acad Sci 1999;878:150-158 (Pubitemid 29353567)
24. Takaishi H, Kimura T, Dalal S, et al. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol 2008;9:47-54. (Pubitemid 351266969)
25. Neuhold LA, Killar L, Zhao W, et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest 2001;107:35-44. (Pubitemid 32047412)
26. Lindy O, Konttinen YT, Sorsa T, et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 1997;40:1391-1399 (Pubitemid 27430949)
27. Westhoff CS, Freudiger D, Petrow P, et al. Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum 1999;42:1517-1527 (Pubitemid 30265611)
28. Moore BA, Aznavoorian S, Engler JA, et al. Induction of collagenase-3 (MMP-13) in rheumatoid arthritis synovial fibroblasts. Biochim Biophys Acta 2000;1502:307-318
29. Konttinen YT, Salo T, Hanemaaijer R, et al. Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol 1999;18:401-412 (Pubitemid 29397452)
30. Petrow PK, Wernicke D, Schulze Westhoff C, et al. Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis. Ann Rheum Dis 2002;61:391-397 (Pubitemid 34496816)
31. Bandara G, Georgescu HI, Lin CW, et al. Synovial activation of chondrocytes: evidence for complex cytokine interactions. Agents Actions 1991;34:285-288
32. Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. Handb Exp Pharmacol 2008;181:101-129
33. Cohen G, Gossec L, Dougados M, et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007;66:358-363 (Pubitemid 46579638)
34. Müller-Ladner U, Pap T, Gay RE, et al. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:102-110
35. Coenen MJ, Toonen EJ, Scheffer H, et al. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 2007;8:761-773 (Pubitemid 47288976)